J&J Split About 'Unleashing' Consumer Business: CEO

Johnson & Johnson announced a major restructuring, splitting into two companies: one focusing on consumer products and the other on pharmaceuticals and medical devices. This decision, driven by market changes and innovation, aims to enhance growth and value for stakeholders. The company plans to maintain its AAA rating and address talc liabilities without affecting the split. The move aligns with evolving strategies and shareholder interests, emphasizing innovation and a strong corporate credo.

What is the primary reason Johnson & Johnson decided to split into two companies?

• To reduce operational costs

• To focus on innovation and market changes

• To increase the number of employees

• To merge with another company

How does Johnson & Johnson view its AAA rating in the context of the company split?

• As a primary goal to maintain

• As a reflection of business operations

• As an unnecessary burden

• As a temporary achievement

What is the expected growth rate for Johnson & Johnson's pharmaceutical and medical device sectors after the split?

• High double digits

• Mid single digits and above

• Low single digits

• No growth expected

How might the split affect the consumer business's ability to adapt to market changes?

• It will slow down operations

• It will have no effect

• It will enhance agility and innovation

• It will limit flexibility

What role does social media play in the consumer business's strategy post-split?

• It is a minor consideration

• It is irrelevant to their strategy

• It is a distraction from core business

• It is a major driver of consumer products

How is the talc liability issue expected to be handled after the company split?

• It will be transferred to the pharmaceutical division

• It will be resolved before the split

• It will remain with the consumer business

• It will be ignored

What is the significance of the credo in the context of the company split?

• It will be shared by both companies

• It will be exclusive to the pharmaceutical division

• It will be exclusive to the consumer division

• It will be discarded